Understand the source comparison
Peptides for Mold Illness: Full Protocol Comparison
This table compares the three primary peptides used in clinical CIRS protocols, their mechanisms, dosing, and application timing. Thymosin Alpha-1 Modulates T-cell differentiation; reduces IL-6, TNF-alpha 0.9–1.6mg subcutaneous, twice weekly, 12–16 weeks Eleva
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- This table compares the three primary peptides used in clinical CIRS protocols, their mechanisms, dosing, and application timing.
- Thymosin Alpha-1
- Modulates T-cell differentiation; reduces IL-6, TNF-alpha
- 0.9–1.6mg subcutaneous, twice weekly, 12–16 weeks
- Elevated TGF-beta-1, chronic fatigue, persistent immune activation after remediation
- First-line immune modulator—use before VIP
- BPC-157
- Promotes angiogenesis, repairs gut epithelium, upregulates VEGF
- 250–500mcg subcutaneous, daily, 4–8 weeks
- Gut permeability, SIBO, oxidative gut damage from mycotoxins
- Essential if GI symptoms or leaky gut present
- VIP (Vasoactive Intestinal Peptide)
- Raises MSH, reduces neuroinflammation, regulates circadian rhythm
- 50mcg intranasal, four times daily, ongoing
- Suppressed MSH, sleep disruption, limbic symptoms after binder phase complete
- Late-stage protocol—requires stable environment